Ori_sent	Par_sent	Target	Ori_pred	Par_pred	Base_bertscore	Revised_paraphrase_scores
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	"Some patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine may require a different dose of @DRUG$, so the recommended dose is 2 mg daily."	DDI-advise	DDI-advise	DDI-advise	0.97	0.993
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"Patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine should be given a recommended dose of DETROL LA 2 mg daily."	0	DDI-advise	DDI-advise	0.966	0.991
"Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine."	"Other drugs which have the potential to increase the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine."	DDI-int	0	0	0.968	0.964
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	"If patients are receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (e.g., @DRUG$, miconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), cyclosporine, or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	DDI-advise	DDI-advise	DDI-advise	0.96	0.972
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily."	"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$), macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	DDI-mechanism	0.979	0.964
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$), the recommended dose of @DRUG$ is 2 mg daily."	DDI-advise	DDI-advise	DDI-advise	0.961	0.957
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	"If patients are receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily."	DDI-advise	DDI-advise	DDI-advise	0.958	0.957
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily."	"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily."	DDI-advise	DDI-advise	DDI-advise	0.954	0.982
Potential for @DRUG$    to Affect Other Drugs @DRUG$ is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.	@DRUG$ is not expected to cause clinically important pharmacokinetic interactions with other drugs that are metabolized by cytochrome P450 isozymes.	0	0	0	0.957	0.967
"Given the primary CNS effects of @DRUG$, @DRUG$ should be used with caution in combination with other centrally acting drugs and alcohol."	"@DRUG$ should be used with caution in combination with other centrally acting drugs and alcohol, given the primary CNS effects of @DRUG$."	0	0	DDI-advise	0.962	0.968
"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other @DRUG$ and @DRUG$."	"As paliperidone has primary CNS effects, INVEGA should be used with caution in combination with other @DRUG$ and @DRUG$."	0	0	0	1	0.965
"Potential for Other Drugs to Affect @DRUG$ @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely."	"There is a potential for other drugs to affect @DRUG$, but @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely."	0	0	0	0.994	0.956
"Mean @DRUG$ plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor."	"When @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor, mean @DRUG$ plasma concentrations were approximately 2-fold higher."	0	0	DDI-mechanism	0.956	0.97
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other medications that inhibit the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.991	0.96
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.96	0.945
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.958	0.968
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.985	0.957
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may affect oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.988	0.962
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of @DRUG$ (i.e., Cmax and AUC)."	DDI-mechanism	0	0	0.99	0.963
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other medications that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC)."	0	0	0	0.988	0.957
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"If @DRUG$ and @DRUG$ are used together, caution is recommended. This is because other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.992	0.955
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other drugs that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.956	0.958
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may slightly alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.957	0.957
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may slightly alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.962	0.956
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), could potentially alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.961	0.959
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Caution is recommended when using @DRUG$ with other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin). This may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	DDI-mechanism	0	DDI-advise	0.992	0.984
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.96	0.978
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may affect oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	0	0	0	0.988	0.951
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may increase or decrease @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	DDI-mechanism	0	0	0.955	0.979
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other medications that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC)."	0	0	0	0.96	0.958
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), can reportedly alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	DDI-mechanism	0	0	0.985	0.986
"Concurrent ingestion of @DRUG$ (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"Ingesting @DRUG$ at the same time (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not have a significant effect on the exposure of oxybutynin or desethyloxybutynin."	0	0	0	0.96	0.963
"Concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"The concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	0	0	0	0.993	0.955
"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	0	0	0	0.987	0.964
"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"There was no significant difference in the exposure of oxybutynin or desethyloxybutynin when taken concurrently with @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$)."	0	0	0	0.957	0.964
"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	0	0	0	0.954	0.959
"Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$."	"The concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not have a significantly noticeable effect on the exposure of oxybutynin or @DRUG$."	0	0	0	0.989	0.966
"Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly change the exposure of oxybutynin or desethyloxybutynin."	0	0	0	0.952	0.988
"Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	"In common with other antacids, concurrent ingestion of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) may change the exposure of @DRUG$ or desethyloxybutynin."	0	0	0	0.954	1
"Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"When taken together, antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) does not significantly affect the exposure of oxybutynin or desethyloxybutynin."	0	0	0	0.995	0.991
"Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin."	"There is no significant effect on the exposure of oxybutynin or desethyloxybutynin when antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) is taken concurrently."	0	0	0	0.982	0.993
"Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	"Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) had no significant effect on the exposure of @DRUG$ or desethyloxybutynin."	0	0	0	0.96	0.954
"Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$."	"Concurrent consumption of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) had no significant impact on exposure to oxybutynin or @DRUG$."	0	0	0	0.96	0.957
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	"It is reported that concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) does not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	0	0	0	0.956	0.955
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) reportedly did not significantly affect the exposure of @DRUG$ or desethyloxybutynin."	0	0	0	0.958	0.99
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$."	"Antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$."	0	0	0	0.953	0.967
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or @DRUG$."	There was no significant effect on the exposure of @DRUG$ or @DRUG$ when taken concurrently with antacid.	0	0	0	0.96	0.966
"@DRUG$ has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$."	"@DRUG$ has been reported to quicken the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, resulting in an increase in dosage requirements for @DRUG$."	0	0	0	0.964	0.964
"Mitotane has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$."	"Mitotane has been reported to speed up the metabolism of @DRUG$ by inducing hepatic microsomal enzymes, which could lead to higher dosage requirements for @DRUG$."	0	0	0	0.957	0.989
"Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering Mitotane to patients on @DRUG$."	"Close monitoring from physicians shall be required for patients when administering Mitotane, in case there is a change in @DRUG$ dosage requirements for the patients on @DRUG$."	0	0	0	0.957	0.991
"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering @DRUG$ to patients on @DRUG$."	close monitoring of patients for a change in anticoagulant dosage requirements is recommended when administering @DRUG$ to patients on @DRUG$.	DDI-advise	0	0	0.956	0.953
Concomitant administration of @DRUG$ and  @DRUG$ has been associated with erythema and histamine-like flushing and anaphylactoid reactions.	"There have been reports of erythema and histamine-like flushing and anaphylactoid reactions when taking @DRUG$ and @DRUG$ together. As a result, caution is advised if these two medications are taken at the same time."	DDI-effect	0	0	0.95	0.989
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring."	"Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, should be used concurrently and/or sequentially with @DRUG$ with careful monitoring."	0	DDI-effect	DDI-advise	0.947	0.976
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring."	"Systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, should be used with caution and under close monitoring."	0	DDI-effect	DDI-advise	0.958	0.987
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful monitoring."	"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful and attentive monitoring."	0	DDI-effect	DDI-advise	0.956	0.955
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring."	"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring and dose adjustment as needed."	0	DDI-effect	DDI-advise	0.959	0.962
"Coadministration of @DRUG$ with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%)."	"Coadministration of @DRUG$ with clarithromycin may result in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%)."	0	0	0	0.953	0.958
"Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%)."	"Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations, increased plasma bismuth trough concentrations, and increased @DRUG$ plasma concentrations."	0	0	0	0.961	0.992
Coadministration with @DRUG$ results in a slight decrease in the rate of @DRUG$ absorption that is clinically unimportant.	"There is a slight decrease in the rate of @DRUG$ absorption when co-administered with @DRUG$, though this is clinically unimportant."	0	DDI-effect	DDI-mechanism	0.953	0.954
Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from TRITEC.	High doses of @DRUG$ (170 mEq) may decrease plasma concentrations of @DRUG$ by 28% and bismuth from TRITEC.	DDI-mechanism	DDI-mechanism	DDI-mechanism	0.968	0.984
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from @DRUG$.	"If you are taking a high dose of antacid (170 mEq), it may reduce the plasma concentrations of @DRUG$ by 28%. Additionally, it may also reduce the amount of bismuth in your blood that comes from @DRUG$."	0	DDI-mechanism	DDI-mechanism	0.954	0.939
"For information on drug interactions associated with @DRUG$, refer to the @DRUG$     package insert."	"For more information on drug interactions associated with @DRUG$, please refer to the @DRUG$ package insert."	0	0	0	0.962	0.995
"However, the co   administration of SPIRIVA with other @DRUG$   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended."	The concomitant administration of SPIRIVA with other @DRUG$-containing drugs (e.g. @DRUG$) has not been studied and is therefore not recommended.	0	0	0	0.992	0.962
Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.	"If you take @DRUG$ and oral @DRUG$ at the same time, the effectiveness of oral contraceptives may be reduced."	DDI-effect	DDI-effect	0	0.994	0.969
"@DRUG$ may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	"@DRUG$ may enhance the effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. This could cause you to feel more tired or sleepy than usual."	DDI-effect	0	0	0.964	0.973
"@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	"@DRUG$ can potentiate the effects of other central nervous system depressants, such as alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers. Therefore, it is important to exercise caution if taking any of these substances togethe"	DDI-effect	0	0	0.969	0.973
"Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	"The sedative effects of triprolidine may be enhanced when it is used with @DRUG$, including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	0	0	0	0.992	0.941
"Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers."	"Triprolidine may enhance the effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers."	0	0	0	0.994	0.945
"Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	"The sedative effects of Triprolidine may be enhanced when taken with central nervous system depressants such as @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers."	0	0	0	0.992	0.95
"Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers."	"It is possible that triprolidine may intensify the sedative effects of central nervous system depressants such as @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers."	0	0	0	0.967	0.945
"Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers."	"Triprolidine may intensify the sedative effects of central nervous system depressants that include @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers."	0	0	0	0.992	0.945
"Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers."	"Triprolidine may intensify the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers."	0	0	0	0.966	0.94
"Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$."	"Caution is recommended when using triprolidine with central nervous system depressants such as @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$, as it may enhance their sedative effects."	0	0	0	0.965	0.945
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, @DRUG$, narcotic analgesics, sedatives, and tranquillisers."	"Triprolidine may amplify the calming effects of central nervous system depressants such as alcohol, @DRUG$, @DRUG$, narcotics, sedatives, and tranquillizers."	0	0	0	0.994	0.942
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, @DRUG$, sedatives, and tranquillisers."	"Triprolidine may enhance the sedative effects of central nervous system depressants, including alcohol, @DRUG$, hypnotics, @DRUG$, and sedatives. These substances may cause drowsiness, impaired coordination, and other side effects."	0	0	0	0.992	0.947
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers."	"If triprolidine is used with central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers, enhanced sedative effects may occur."	0	0	0	0.966	0.979
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers."	"Triprolidine may amplify the sedative effects of central nervous system depressants such as alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers."	0	0	0	0.965	0.981
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$."	"Triprolidine may enhance the sedative effects of central nervous system depressants, including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$."	0	0	0	0.992	0.952
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers."	"Triprolidine may intensify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers."	0	0	0	0.965	0.946
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$."	"The sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$ may be enhanced by triprolidine."	0	0	0	0.996	0.967
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$."	"Triprolidine may enhance the sedative effects of central nervous system depressants, including but not limited to alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$."	0	0	0	0.986	0.976
"The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine."	"The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants, may be enhanced when triprolidine is administered at the same time."	0	0	0	0.996	0.972
"The effects of @DRUG$, such as atropine and @DRUG$ may be enhanced by the concomitant administration of triprolidine."	"The effects of @DRUG$, such as atropine and @DRUG$, may be enhanced when triprolidine is also taken."	0	0	0	0.992	0.97
"The effects of @DRUG$, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$."	"The effects of @DRUG$ may be enhanced by the concomitant administration of @DRUG$, such as atropine and tricyclic antidepressants."	DDI-effect	0	0	0.995	0.971
"The effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be enhanced by the concomitant administration of triprolidine."	"The combined effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be more evident when triprolidine is also administered."	0	0	0	0.991	0.94
"The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$."	"The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants, may be increased when taken at the same time as @DRUG$."	DDI-effect	0	0	0.992	0.977
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$."	"We recommend clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$."	DDI-advise	0	DDI-mechanism	0.964	0.954
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"There are a number of potent CYP 3A4 inhibitors which can interfere with the absorption of @DRUG$. These include macrolide antibiotics such as erythromycin, troleandomycin, and clarithromycin, HIV protease or reverse transcriptase inhibitors such as ritonavir, indinavir, and nelfinavir, or @DRUG$ such as ketoconazole, itraconazole, and voriconazole."	0	DDI-effect	DDI-mechanism	0.993	0.986
"@DRUG$ can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and alcohol."	"There is the potential for @DRUG$ to interact with @DRUG$, anticholinergic drugs, tricyclic antidepressants, monoamine oxidase inhibitors, and alcohol. It is advisable to exercise caution if using these substances together."	DDI-int	DDI-advise	0	0.967	0.94
"For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"The recommended dose of DETROL LA for patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine is 2 mg daily."	0	DDI-advise	0	0.954	0.995
"For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.969	0.981
"For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"For patients receiving @DRUG$ or other strong CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.972	0.99
"For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"For patients receiving @DRUG$ or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily. CYP3A4 inhibitors include other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine."	0	DDI-advise	0	0.96	0.984
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"When taking ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.961	0.953
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.967	0.974
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"When patients are receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.969	0.963
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking ketoconazole or other CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole), macrolide antibiotics (eg, erythromycin, clarithromycin), cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.957	0.96
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"When receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.967	0.962
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.967	0.968
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"When taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.962	0.954
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking ketoconazole or other strong inhibitors of CYP3A4 such as other azole antifungals (eg, itraconazole, miconazole), macrolide antibiotics (eg,@DRUG$, @DRUG$), cyclosporine, or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.958	0.965
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily."	"If you are taking ketoconazole or other medications that can inhibit CYP3A4 enzyme activity (such as other azole antifungals like itraconazole or miconazole, macrolide antibiotics like erythromycin or @DRUG$, or @DRUG$ or vinblastine), the recommended dose of DETROL LA is 2 mg daily."	0	DDI-advise	0	0.962	0.966
"Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other @DRUG$ and alcohol."	"Given the primary CNS effects of @DRUG$, it is best to use caution when combining it with other @DRUG$ or alcohol."	DDI-advise	0	DDI-advise	0.989	0.991
"Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$."	"Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$."	DDI-advise	0	DDI-advise	0.994	0.963
@DRUG$ may antagonize the effect of @DRUG$ and other dopamine agonists.	@DRUG$ may reduce the efficacy of @DRUG$ and other dopamine agonists.	DDI-effect	0	DDI-effect	0.96	0.94
@DRUG$ may antagonize the effect of levodopa and other @DRUG$.	@DRUG$ may reduce the efficacy of levodopa and other @DRUG$.	DDI-effect	0	DDI-effect	0.957	0.939
"The concomitant use of @DRUG$ with other @DRUG$ or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects."	"The simultaneous use of @DRUG$ with other @DRUG$ medications or agents which can cause dry mouth, constipation, drowsiness, and/or other anticholinergic-like side effects may make these effects more common and/or more severe."	DDI-effect	0	DDI-effect	0.994	0.99
"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with @DRUG$, a potent CYP3A4 inhibitor."	"Mean oxybutynin chloride plasma concentrations increased approximately two-fold when administered with @DRUG$, a potent CYP3A4 inhibitor."	DDI-mechanism	0	DDI-mechanism	0.99	0.995
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC)."	"Other enzymes which may inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may cause @DRUG$'s mean pharmacokinetic parameters (i.e., Cmax and AUC) to change."	DDI-mechanism	0	DDI-mechanism	0.952	0.959
"@DRUG$ has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin."	"@DRUG$ has been said to quicken the metabolism of @DRUG$ by the means of hepatic microsomal enzyme induction, ultimately calling for a greater dosage of warfarin."	DDI-mechanism	0	DDI-mechanism	0.952	0.991
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	0	DDI-effect	0	0.959	0.963
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	"Other potentially harmful drugs, such as @DRUG$, aminoglycosides, @DEMOGRAPHIC$, polymyxin B, colistin, viomycin, or cisplatin, may have an effect on AUGMENTIN XR when used concurrently or sequentially. Close monitoring is advised when these drugs are indicated."	0	DDI-effect	0	0.955	0.996
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	"With the concurrent and/or sequential use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, it is necessary to monitor usage carefully."	0	DDI-effect	0	0.963	0.965
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring."	"If you're using other potentially hazardous drugs concurrently or sequentially, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, be sure to monitor the situation closely."	0	DDI-effect	0	0.952	0.992
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring."	"If other potentially neurotoxic and/or nephrotoxic drugs are being used concurrently or sequentially, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, careful monitoring is required."	0	DDI-effect	0	0.964	0.997
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring."	"When using @DRUG$ concurrently or sequentially with other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, or viomycin, careful monitoring is required."	0	DDI-effect	0	0.955	0.964
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	"The concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, requires careful monitoring when indicated."	0	DDI-effect	0	0.963	0.965
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	The use of other potentially neurotoxic and/or nephrotoxic drugs concurrently or sequentially with @DRUG$ requires careful monitoring.	0	DDI-effect	0	0.995	0.994
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring."	"Concurrent or sequential use of other potentially neurotoxic or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, requires careful monitoring."	0	DDI-effect	0	0.986	0.966
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring."	"Systemic or topical use of other drugs that could potentially cause neuro- or nephrotoxicity, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, needs to be carefully monitored when concurrent or sequential use is indicated."	0	DDI-effect	0	0.964	0.957
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring."	"Other potentially neurotoxic and nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, require concurrent and/or sequential careful monitoring."	0	DDI-effect	0	0.978	0.965
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring."	"When other potentially neurotoxic and/or nephrotoxic drugs are used concurrently or sequentially, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, careful monitoring is required."	0	DDI-effect	0	0.958	0.966
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring."	Careful monitoring is required when using other potentially neurotoxic and/or nephrotoxic drugs concurrently or sequentially with @DRUG$.	0	DDI-effect	0	0.986	0.992
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring."	"If other potentially neurotoxic and/or nephrotoxic drugs are used concurrently or sequentially, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, careful monitoring is required."	0	DDI-effect	0	0.988	0.992
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring."	"There is a potential for drug interactions when using multiple potentially neurotoxic or nephrotoxic drugs concurrently or sequentially. Careful monitoring is required when using drugs such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$."	0	DDI-effect	0	0.96	0.997
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$, when indicated, requires careful monitoring."	"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs requires careful monitoring. Drugs that may require special monitoring include amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$."	0	DDI-effect	0	0.988	0.996
"Coadministration of @DRUG$ with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%)."	"Coadministration of @DRUG$ with @DRUG$ resulted in higher plasma ranitidine concentrations (57%), higher plasma bismuth trough concentrations (48%), and higher 14- hydroxy- clarithromycin plasma concentrations (31%)."	DDI-mechanism	0	DDI-mechanism	0.985	0.967
"These include @DRUG$, @DRUG$, and oral and inhaled steroids."	"These drugs include @DRUG$, @DRUG$, and oral and inhaled steroids."	0	DDI-effect	0	0.953	0.994
"However, the co   administration of @DRUG$ with other @DRUG$   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended."	"Although the co-administration of @DRUG$ with other @DRUG$-containing drugs has not been studied, it is not recommended at this time."	DDI-advise	0	DDI-advise	0.963	0.993
"However, the co   administration of @DRUG$ with other anticholinergic   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended."	"@DRUG$ co-administration with other anticholinergic drugs (e.g., @DRUG$) has not been studied and is, therefore, not recommended."	DDI-advise	0	DDI-advise	0.96	0.993
Concurrent use of antibacterial drugs with oral @DRUG$ may render oral @DRUG$ less effective.	"The use of oral @DRUG$ alongside other antibacterial drugs may reduce the effectiveness of the @DRUG$. Therefore, it is important to speak to a healthcare professional before taking both medications together."	0	DDI-effect	0	0.953	0.942
"CYP 3A4 Inhibitors (e.g. @DRUG$ and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities."	There have been some reports of serious adverse events when certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) are taken with potent CYP 3A4 inhibitors (e.g. @DRUG$ and @DRUG$). These events can include vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	DDI-effect	0	0.961	0.964
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities."	There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors. These events have resulted in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	DDI-effect	0	0.994	0.986
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities."	"Cases of serious adverse events including vasospasm, cerebral ischemia, and extremity ischemia have been reported in rare instances when certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) are coadministered with potent CYP 3A4 inhibitors."	0	DDI-effect	0	0.995	0.991
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.987	0.967
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include @DRUG$ (for example, erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (for example, ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (for example, ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.956	0.955
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.957	0.955
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.985	0.988
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some potential CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.982	0.972
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.955	0.999
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of medications that can increase the potency of CYP 3A4 include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.957	0.999
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of more potent CYP 3A4 inhibitors include @DRUG$ (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (such as ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (such as ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.972	0.984
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.973	0.983
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"CYP 3A4 inhibitors such as @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole) can be more potent."	0	DDI-effect	0	0.979	0.991
"Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some CYP 3A4 inhibitors that may be more potent include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.971	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.992	0.991
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.989	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"CYP 3A4 inhibitors like macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole) can reduce the efficacy of AUGMENTIN XR."	0	DDI-effect	0	0.989	0.958
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.962	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.956	0.999
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). As a result, concomitant administration of @DRUG$ and @DRUG$ should be avoided."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of more potent CYP 3A4 inhibitors are macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.955	0.991
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that may have a stronger effect include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.983	0.995
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.961	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.989	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.991	0.995
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.966
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of medications that can inhibit CYP 3A4 and should be avoided when taking @DRUG$ include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.997
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that can have a stronger effect include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.989	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.991	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"CYP 3A4 inhibitors can include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.992
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.996	0.991
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.992
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Description: Some CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent inhibitors of CYP 3A4 include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.987
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.992	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.996	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.994	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some examples of powerful CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.987	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$@DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$@DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These substances have been reported to have a more potent effect."	0	DDI-effect	0	0.996	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.997
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some examples of medications that can inhibit CYP 3A4 include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.995	0.992
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.996	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (like erythromycin, troleandomycin, and clarithromycin), HIV protease or @DRUG$ (such as @DRUG$, indinavir, nelfinavir, and delavirdine), or azole antifungals (for example, ketoconazole, itraconazole, and voriconazole)."	0	DDI-effect	0	0.996	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.997	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.995
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some potential CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some examples of more potent CYP 3A4 inhibitors are macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.994	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent Cyprus 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.993	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"CYP 3A4 inhibitors such as macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$) can have a more potent effect."	0	DDI-effect	0	0.995	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.995	0.992
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.996	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some examples of CYP 3A4 inhibitors that may have a more significant impact include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.992	0.978
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"CYP 3A4 inhibitors can include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.994	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.992	0.995
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.996	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.996	0.997
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.995
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.993	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.996	0.968
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole)."	0	DDI-effect	0	0.995	0.996
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$)."	"CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). These more potent inhibitors can cause @DRUG$ to have a more pronounced effect."	0	DDI-effect	0	0.99	0.989
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole)."	"Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole)."	0	DDI-effect	0	0.99	0.965
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$)."	"Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine), or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$)."	0	DDI-effect	0	0.997	0.993
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$)."	0	DDI-effect	0	0.994	0.994
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$)."	"Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$)."	0	DDI-effect	0	0.995	0.993
"Less potent inhibitors include @DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole."	"@DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole are less potent inhibitors."	0	DDI-effect	0	0.995	0.994
"Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole."	"Given that less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole, it is difficult to say with certainty which is more impactful."	0	DDI-effect	0	0.988	0.992
"Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole."	"@DRUG$ is a less potent inhibitor that has been linked with nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole."	0	DDI-effect	0	0.99	0.99
"Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole."	"Some less potent inhibitors of cYP3A4 include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole."	0	DDI-effect	0	0.992	0.989
"Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole."	"Inhibitors that are less potent include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole."	0	DDI-effect	0	0.992	0.99
"Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole."	"Some less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole."	0	DDI-effect	0	0.99	0.991